Multiple targets (Sangdan Tongluo Granule)

Sangdan Tongluo Granule is a Traditional Chinese Medicine (TCM) formulation primarily indicated for the treatment of diabetic peripheral neuropathy (DPN) and related vascular complications. The target profile for this formulation is not a single molecular entity but a complex network of proteins and signaling pathways inferred from the pharmacological profiles of its constituent herbs, such as Morus alba (Sangye) and Salvia miltiorrhiza (Danshen), as well as analog formulas like Tongmai Granule. Research using network pharmacology suggests that these granules modulate key nodes including Tumor Necrosis Factor (TNF), Interleukin-6 (IL-6), and Vascular Endothelial Growth Factor A (VEGFA) to exert anti-inflammatory, antioxidant, and pro-angiogenic effects (PMID: 33542704, 31258545). By targeting these pathways, the formulation aims to improve microcirculation and provide neuroprotection, a process described in TCM as unblocking the collaterals (Tongluo). While the specific molecular interactome for Sangdan Tongluo Granule is not as strictly defined as a monoclonal antibody target, its therapeutic efficacy is attributed to the synergistic action of multiple phytochemicals on these diverse biological targets. This multi-target approach is designed to address the multifactorial nature of DPN, though it presents challenges for standard pharmacokinetic and pharmacodynamic modeling.

Other names

Sangdan Tongluo Granule targetsTongluo/Tongmai analog targetsDiabetic peripheral neuropathy TCM targets

Synergistic modulation of inflammatory cytokines (TNF, IL-6) and growth factors (VEGF) to improve microvascular perfusion and nerve health.